EWA
CRL icon

Exencial Wealth Advisors’s Charles River Laboratories CRL Stock Holding History

Exencial Wealth Advisors’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$485K Sell
2,810
-76
-3% -$14.1K 0.02% 404
2025
Q4 		$576K Buy
2,886
+87
+3% +$15.8K 0.02% 370
2025
Q3 		$438K Buy
2,799
+153
+6% +$24.3K 0.01% 400
2025
Q2 		$401K Buy
2,646
+33
+1% +$4.4K 0.01% 400
2025
Q1 		$393K Buy
+2,613
New +$438K 0.01% 393

Other funds holding CRL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Harris Associates
Harris Associates Chicago, Illinois $75.4B AUM 14.46% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Exencial Wealth Advisors's CRL Position: Q1 2026 in Review

Exencial Wealth Advisors reduced its Charles River Laboratories (CRL) stake by 2.6% in Q1 2026, selling an estimated $14.1K and leaving 2,810 shares worth $485K. The position accounts for 0.02% of the portfolio, ranked #404.

Exencial Wealth Advisors first reported a position in CRL in Q1 2025 and has held it in 5 quarters since. The position peaked at $576K in Q4 2025. 559 funds tracked by Wall St. Rank hold CRL as of Q1 2026.

  • Exencial Wealth Advisors held 2,810 shares of Charles River Laboratories worth $485K as of Q1 2026.
  • Exencial Wealth Advisors sold 76 Charles River Laboratories shares in Q1 2026, an estimated $14.1K.
  • Charles River Laboratories made up 0.02% of Exencial Wealth Advisors's portfolio in Q1 2026, its #404 holding.
  • Exencial Wealth Advisors first reported a position in Charles River Laboratories in Q1 2025 and has held it in 5 quarters since.
  • Exencial Wealth Advisors's Charles River Laboratories position peaked at $576K in Q4 2025.
  • 559 funds tracked by Wall St. Rank held Charles River Laboratories as of Q1 2026.

Based on Exencial Wealth Advisors's 13F filing for Q1 2026, filed 28 Apr 2026.